HB 453 would create a Kentucky prescription-drug cost-sharing rule that generally prohibits insurers, pharmacy benefit managers, and other pharmacy-benefit administrators from requiring an insured to pay more in cost sharing for a covered prescription drug than the drug’s cash price. The bill defines “cash price” broadly to include prices available directly to consumers through cards, programs, websites, or other lawful mechanisms, and it requires insurers to count qualifying cash-price payments toward a member’s cost-sharing obligations. It also requires insurers to maintain written procedures for documenting cash-price payments and to ensure pharmacy contracts require compliance with the new rule.
The bill extends these requirements to a wide range of coverage arrangements, including limited health service benefit plans, limited health service organizations, and certain public employee and postsecondary institution self-insured plans. It also gives pharmacies the right to tell insureds about the rule and requires pharmacies to submit proof of cash-price payments to insurers. The bill includes exceptions for certain self-insured plans tied to public employees, and it delays application if compliance would cause a health plan to lose HSA-qualified high-deductible status until the deductible is met. The effective date is January 1, 2027, and the new pharmacy compliance section is placed in Chapter 315.
Impact
HB 453 would amend KRS 304.17A-164 and related statutes governing health plans, limited health service plans, and public employee and postsecondary institution health coverage. It would add a new statutory requirement that prescription-drug cost sharing cannot exceed the cash price and would require insurers and pharmacy benefit managers to recognize and credit cash-price payments toward deductibles or other cost-sharing obligations. It also creates a new Chapter 315 requirement directing pharmacies to comply with the proof-submission rule. The bill would apply to health plans issued or renewed on or after January 1, 2027, and would affect insurers, PBMs, pharmacies, public employee plans, university plans, and insured consumers who pay cash for prescriptions.
Sentiment
Based on the bill text and the lack of recorded committee testimony or votes in the provided materials, the overall sentiment appears to be policy-driven and consumer-protection oriented, with the bill aiming to reduce prescription-drug out-of-pocket costs and improve transparency. The structure of the bill suggests an effort to standardize how cash payments are treated across multiple types of coverage and public plans. Because no committee discussion or vote history is provided, there is no documented public support or opposition in the record supplied here.
Contention
The main points of contention likely involve the bill’s effect on insurer and PBM cost-sharing design, administrative burden, and interaction with federal law and high-deductible health plans. The bill expressly limits its requirements to the extent permitted under federal law and creates an exception where compliance would jeopardize HSA-qualified high-deductible status. Another likely issue is the broad reach of the bill into public employee plans, Medicare-related supplemental coverage, Medicare Part D-related limited health service plans, and pharmacy contracts, which may raise concerns among insurers, employers, and plan administrators about implementation costs and operational complexity. Pharmacies are also directly affected because they must provide information to insureds and submit proof of cash-price payments.